The mTOR–SREBP1 axis provides crosstalk between oncogenic signaling and cancer metabolism, and co-inhibition of metabolism and oncogenic signaling pathways is a strategy to improve treatment efficacy [1,6,10]. This evidence concerns the gene MTOR and cancer.